A soluble lymphocyte activation gene-3 (sLAG-3) protein as a prognostic factor in human breast cancer expressing estrogen or progesterone receptors
Authors:
- Frédéric TriebelFTFrédéric Triebel
- Kamel HaceneKHKamel Hacene
- Marie-France PichonMPMarie-France Pichon
- 1 April 2006
- journal article
- Published by Elsevier in Cancer Letters
- Vol. 235 (1) , 147-153
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Immunological mechanisms elicited at the tumour site by lymphocyte activation gene‐3 (LAG‐3) versus IL‐12: sharing a common Th1 anti‐tumour immune pathwayThe Journal of Pathology, 2004
- Role of LAG-3 in Regulatory T CellsImmunity, 2004
- The immunophenotype and activation status of the lymphocytic infiltrate in human breast cancers, the role of the major histocompatibility complex in cell-mediated immune mechanisms, and their association with prognostic indicatorsSurgery, 2003
- MHC class II signal transduction in human dendritic cells induced by a natural ligand, the LAG-3 protein (CD223)Blood, 2003
- In Breast Carcinoma Tissue, Immature Dendritic Cells Reside within the Tumor, Whereas Mature Dendritic Cells Are Located in Peritumoral AreasJournal of Experimental Medicine, 1999
- Review Article The immunology and immunotherapy of breast cancer: an updateInternational Journal of Immunopharmacology, 1999
- Opposite role for interleukin‐4 and interferon‐γ on CD30 and lymphocyte activation gene‐3 (LAG‐3) expression by activated naive T cellsEuropean Journal of Immunology, 1997
- CD4/major histocompatibility complex class II interaction analyzed with CD4‐ and lymphocyte activation gene‐3 (LAG‐3)‐Ig fusion proteinsEuropean Journal of Immunology, 1995
- LAG-3, a novel lymphocyte activation gene closely related to CD4.Journal of Experimental Medicine, 1990
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958